Merck chief concerned over future U.S. biopharma innovation

Merck ($MRK) CEO Kenneth Frazier has weighed in on some of the U.S. biopharmaceutical industry's most pressing issues in an opinion piece in the Wall Street Journal. He warns that weak protections on drug patents, drug pricing policies and the high cost of drug development threaten the global leadership of the U.S. biopharma industry. The op-ed calls on policymakers to take actions that would support further innovation in biopharma. Item

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.